TABLE 5.

Mean difference (95% CI) in rate of change in global score^* between the N‐3 and placebo groups: Effect modification by risk factors for cognitive decline

Abbreviations: CI, confidence interval; CTSC‐Cog, subset that received in‐person interviews at the Harvard Clinical and Translational Science Center for VITAL in Boston, MA; CVD, cardiovascular disease; VITAL‐Cog, subset that received telephone cognitive interviews in VITAL.

^*For definitions of the global scores for the two populations, see footnote for Table 2.

^† Mean difference in annual rate of decline of n‐3 – placebo groups from multivariable‐adjusted linear mixed models: see footnotes for Tables 2 and 3. The stratified analyses were done among those with non‐missing data on the effect modifier.

^‡ None of the interaction terms were significant at the Bonferroni‐corrected significance threshold of P = .0036 (= 0.05/14 other modifiers): p‐interaction≥0.04

^.§ Stratum‐specific estimates and interaction terms were pooled using Dersimonian and Laird fixed‐effects method for meta‐analysis ³² except for where the P for heterogeneity across the two substudies for the interaction term for age was < 0.05 (P = .03) and results were meta‐analyzed with random‐effects.

^|| See footnote in Table 1 for definition of depression.

^**Median for the global score was 0.05 in both the VITAL‐Cog and the CTSC‐Cog.

^†† Compliance is defined as self‐reported taking of ≥two‐thirds of pills on all the follow‐up questionnaires between the first and the second cognitive assessment and not initiating out‐of‐study fish oil supplementation.